



May 15, 2017

## **Syndax Pharmaceuticals to Present at the 2017 UBS Global Healthcare Conference**

WALTHAM, Mass., May 15, 2017 (GLOBE NEWSWIRE) -- Syndax Pharmaceuticals, Inc. (Nasdaq:SNDX), a clinical stage biopharmaceutical company developing entinostat and SNDX-6352 in multiple cancer indications, today announced that Chief Executive Officer Briggs W. Morrison, M.D., will present at the 2017 UBS Global Healthcare Conference on May 22, 2017 at 11:30 am EDT at the Grand Hyatt New York.

A live webcast of the Company's presentation can be accessed from the Investor section of the Company's website at [www.syndax.com](http://www.syndax.com), where a replay of the event will also be available for a limited time.

### **About Syndax Pharmaceuticals, Inc.**

Syndax is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Our lead product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from our Phase 2b clinical trial, ENCORE 301, is currently being evaluated in a Phase 3 clinical trial for advanced hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer. Given its potential ability to block the function of immune suppressive cells in the tumor microenvironment, entinostat is also being evaluated in combination with approved PD-1 antagonists. Ongoing Phase 1b/2 clinical trials combine entinostat with KEYTRUDA® from Merck & Co., Inc. for non-small cell lung cancer and melanoma; with TECENTRIQ® from Genentech, Inc. for TNBC; and with BAVENCIOTM from Pfizer Inc. and Merck KGaA, Darmstadt, Germany, for ovarian cancer. Our second product candidate, SNDX-6352, is a monoclonal antibody that blocks the CSF-1 receptor and may also block the function of immune suppressive cells in the tumor microenvironment. SNDX-6352 is being evaluated in a single ascending dose Phase 1 clinical trial and is expected to be developed to treat a variety of cancers.

Investor Contact  
Heather Savelle  
Argot Partners  
[heather@argotpartners.com](mailto:heather@argotpartners.com)  
Tel 617.340.6072

Media Contact  
Eliza Schleifstein  
Argot Partners  
[eliza@argotpartners.com](mailto:eliza@argotpartners.com)  
Tel 973.361.1546